Springtime for Biden
Possible immunopathology from vaccine: Antibody-Dependent Enhancement
Definition and Explanation:
In reacting either to an infection or a vaccine, your body makes antibodies of various types to a variety of proteins on the surface of the virus. Some of the antibodies will be neutralizing, meaning that when they bind to the virus they prevent the virus from getting inside human cells. Other antibodies can likewise bind to the virus, but not make any difference to the virus’s successful functioning. These are non-neutralizing antibodies.
The problem is that both types of antibodies can also bind with loose viral proteins, especially from a vaccine, or a subsequent exposure to another virus, or with proteins of similar shape on or in human cells themselves. When antibodies bind to a loose protein, this triggers what’s called an immune complex reaction.
Immune complexes tend to deposit in certain parts of the body, such as the joints and kidneys. Antibody-Dependent Enhancement (ADE) appears to be a damaging inflammatory reaction of one’s own antibodies against one’s own tissues or cells, again, provoked by antibodies binding to one’s tissues or by immune complexes being deposited.
The antibody/antigen reaction triggers other inflammatory cells in a cascade effect, leading to tissue and organ damage which can be very serious.
https://rivercitymalone.com/health/covid-vaccine-the-problem-of-antibody-dependent-enhancement/
Excerpt
Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease
"A recent study revealed IgG-mediated acute lung injury in vivo in macaques infected with SARS that correlated with a vaccine-elicited, neutralising antibody response. Inflammation and tissue damage in the lung in this animal model recapitulated the inflammation and tissue damage in the lungs of SARS-infected patients who succumbed to the disease. The time course was also similar, with the worst damage occurring in delayed fashion in synchrony with ramping up of the immune response. Remarkably, neutralising antibodies controlled the virus in the animal, but then would precipitate a severe, tissue-damaging, inflammatory response in the lung. This is a similar profile to immune complex-mediated disease seen with RSV vaccines in the past, wherein vaccinees succumbed to fatal enhanced RSV disease because of the formation of antibody-virus immune complexes that precipitated harmful, inflammatory immune responses."
"Current data on COVID-19 vaccines is limited, but does not so far reveal evidence of ADE of disease. Non-human primate studies of Moderna's mRNA-1273 vaccine showed excellent protection, with no detectable immunopathology.13 Phase 1 trials of several vaccines have not reported any immunopathology in subjects administered the candidate vaccines. However, these subjects were unlikely to have yet encountered circulating virus.14 Nevertheless, all preclinical studies to date have been performed with the Wuhan or closely related strains of the virus, while a mutant D614G virus is now the most prevalent circulating form. Several observations suggest that this alternative form may be antigenically distinct from the Wuhan derived strain, not so much in composition, but in conformation of the viral spike and exposure of neutralisation epitopes. Similarly, Phase 1 and 2 clinical trials of vaccine candidates have only been designed around immunogenicity as an efficacy end point and have not been designed to capture exposure of subjects to circulating virus after vaccination, which is when ADE/immunopathology is designed to occur. Thus, the absence of ADE evidence in COVID-19 vaccine data so far does not absolve investigators from disclosing the risk of enhanced disease to vaccine trial participants, and it remains a realistic, non-theoretical risk to the subjects."
"Given the strong evidence that ADE is a non-theoretical and compelling risk for COVID-19 vaccines and the “laundry list” nature of informed consents, __disclosure of the specific risk of worsened COVID-19 disease from vaccination calls for a specific, separate, informed consent form and demonstration of patient comprehension in order to meet medical ethics standards.The informed consent process for on-going COVID-19 vaccine trials does not appear to meet this standard.___
While the COVID-19 global health emergency justifies accelerated vaccine trials of candidates with known liabilities, such an acceleration is not inconsistent with additional attention paid to heightened informed consent procedures specific to COVID-19 vaccine risks."
https://docs.google.com/viewerng/viewer?url=https://rivercitymalone.com/wp-content/uploads/2021/01/Informed-Consent-article-final.pdf
Antibody-dependent enhancement of coronavirus
Jieqi Wen, Yifan Cheng, Rongsong Ling, Yarong Dai, Boxuan Huang, Wenjie Huang,
Siyan Zhang, Yizhou Jiang*
Institute for Advanced Study, Shenzhen University, Shenzhen 518067, China
Accepted 7 May 2020
"...The novel coronavirus poses a great challenge and has caused a wave of panic. In this review, antibody-dependent enhancements in dengue virus and two kinds of coronavirus are summarized. Possible solutions for the effects are reported. We also speculate that ADE may exist in SARS-CoV-2."
"Our understanding of ADE has been relatively thorough up to now. However, the detailed mechanism of ADE and how to resolve this in coronavirus infections is not yet totally clear. From previous research on ADE in other coronaviruses, in particular SARS-CoV and MERS-CoV, it appears that the existence of ADE will elicit more severe body injury, while actually reducing the viral load at the same time. This may affect the results of vaccine therapy. The presence of this phenomenon in these two coronaviruses indicates a potential risk in the vaccine therapy for the novel coronavirus SARS-CoV-2, as it shares the same viral receptor and similar genome sequence with SARS-CoV. SARS-CoV-2 may have a similar mechanism of viral entry and thus may share similar mechanisms of ADE. This novel coronavirus has not long been known, so studies in this field have not yet led to any conclusions."
"...Understanding of ADE in SARS-CoV and MERS-CoV infections has taken several years and was relatively clear till these two years. From this, we speculate that studies on ADE in this newly emerged coronavirus will take some time, but the elucidation of this effect is of great importance."
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://docs.google.com/viewerng/viewer?url=https://rivercitymalone.com/wp-content/uploads/2021/01/Antibody-depent-enhancement.pdf
https://www.sciencedirect.com/science/article/abs/pii/S1286457920300484
Amazing Polly: Boom - Guess who Fauci's Wife is?
Christine Grady
Head of Bioethics and Human Subject Research at NIH
Search for an AIDS Vaccine - Christine Grady, 1995
"Painstaking analysis of the knotty ethical problems involved in human-subjects research and a well thought-out proposal for a community approach to conducting field trials for an HIV vaccine."
Fauci Presents NIAID Strategy for HIV Vaccine Development, 1996
Abstract
"Dr. Fauci is optimistic that a useful HIV vaccine can be developed, ___despite economic, ethical, and cultural constraints."__
https://www.bitchute.com/video/7oGqggv7I5rD/